Hemophilia: State of the art of hematologic care 1988

C. K. Kasper, J. B. Graham, P. B A Kernoff, M. J. Larrieu, K. A. Rickard, P. M. Mannucci

Research output: Contribution to journalArticle

Abstract

Since 1982, when the World Federation of Hemophilia first published a document on the state of the art of hemophilia diagnosis and care, there have been lights and shadows in this field. Although the widespread infection of hemophiliacs with the human immunodeficiency virus (HIV) contaminting clotting factor concentrates is still a threatening and formidable shadow, the gloomy picture brought about by the AIDS epidemic is partially lightened by spectacular improvements in therapy and diagnosis. Carrier detection and first-trimester prenatal diagnosis can now be performed accurately in most kindreds by analysis of DNA of the factor VIII or IX genes. An important step forward towards the elimination of the risk of blood-borne infections transmitted by plasma products was recently made through the application of virucidal methods to clotting factor concentrates. Since HIV appears more vulnerable to such methods than the hepatitis viruses, currently available concentrates can be considered substantially free from the risk of transmitting HIV infection. Even though transmission of hepatitis is much reduced but not totally abolished, virucidal methods are continuously being improved, so that it can be foreseen that concentrates will become safer and safer. Finally, factor VIII produced by recombinant DNA technology is undergoing the first clinical trials in hemophiliacs. Hopefully, it will free from the risk of transmitting infections and will be available in sufficiently large amounts to meet the need of hemophiliacs worldwide.

Original languageEnglish
Pages (from-to)141-144
Number of pages4
JournalVox Sanguinis
Volume56
Issue number3
Publication statusPublished - 1989

Fingerprint

Hemophilia A
Blood Coagulation Factors
Factor VIII
HIV
Infection
Hepatitis Viruses
Personal Autonomy
Factor IX
Recombinant DNA
Virus Diseases
First Pregnancy Trimester
Prenatal Diagnosis
Hepatitis
Acquired Immunodeficiency Syndrome
Clinical Trials
Technology
Light
DNA
Genes
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Kasper, C. K., Graham, J. B., Kernoff, P. B. A., Larrieu, M. J., Rickard, K. A., & Mannucci, P. M. (1989). Hemophilia: State of the art of hematologic care 1988. Vox Sanguinis, 56(3), 141-144.

Hemophilia : State of the art of hematologic care 1988. / Kasper, C. K.; Graham, J. B.; Kernoff, P. B A; Larrieu, M. J.; Rickard, K. A.; Mannucci, P. M.

In: Vox Sanguinis, Vol. 56, No. 3, 1989, p. 141-144.

Research output: Contribution to journalArticle

Kasper, CK, Graham, JB, Kernoff, PBA, Larrieu, MJ, Rickard, KA & Mannucci, PM 1989, 'Hemophilia: State of the art of hematologic care 1988', Vox Sanguinis, vol. 56, no. 3, pp. 141-144.
Kasper CK, Graham JB, Kernoff PBA, Larrieu MJ, Rickard KA, Mannucci PM. Hemophilia: State of the art of hematologic care 1988. Vox Sanguinis. 1989;56(3):141-144.
Kasper, C. K. ; Graham, J. B. ; Kernoff, P. B A ; Larrieu, M. J. ; Rickard, K. A. ; Mannucci, P. M. / Hemophilia : State of the art of hematologic care 1988. In: Vox Sanguinis. 1989 ; Vol. 56, No. 3. pp. 141-144.
@article{ec0f73889b714423a6ac0a099038682c,
title = "Hemophilia: State of the art of hematologic care 1988",
abstract = "Since 1982, when the World Federation of Hemophilia first published a document on the state of the art of hemophilia diagnosis and care, there have been lights and shadows in this field. Although the widespread infection of hemophiliacs with the human immunodeficiency virus (HIV) contaminting clotting factor concentrates is still a threatening and formidable shadow, the gloomy picture brought about by the AIDS epidemic is partially lightened by spectacular improvements in therapy and diagnosis. Carrier detection and first-trimester prenatal diagnosis can now be performed accurately in most kindreds by analysis of DNA of the factor VIII or IX genes. An important step forward towards the elimination of the risk of blood-borne infections transmitted by plasma products was recently made through the application of virucidal methods to clotting factor concentrates. Since HIV appears more vulnerable to such methods than the hepatitis viruses, currently available concentrates can be considered substantially free from the risk of transmitting HIV infection. Even though transmission of hepatitis is much reduced but not totally abolished, virucidal methods are continuously being improved, so that it can be foreseen that concentrates will become safer and safer. Finally, factor VIII produced by recombinant DNA technology is undergoing the first clinical trials in hemophiliacs. Hopefully, it will free from the risk of transmitting infections and will be available in sufficiently large amounts to meet the need of hemophiliacs worldwide.",
author = "Kasper, {C. K.} and Graham, {J. B.} and Kernoff, {P. B A} and Larrieu, {M. J.} and Rickard, {K. A.} and Mannucci, {P. M.}",
year = "1989",
language = "English",
volume = "56",
pages = "141--144",
journal = "Vox Sanguinis",
issn = "0042-9007",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Hemophilia

T2 - State of the art of hematologic care 1988

AU - Kasper, C. K.

AU - Graham, J. B.

AU - Kernoff, P. B A

AU - Larrieu, M. J.

AU - Rickard, K. A.

AU - Mannucci, P. M.

PY - 1989

Y1 - 1989

N2 - Since 1982, when the World Federation of Hemophilia first published a document on the state of the art of hemophilia diagnosis and care, there have been lights and shadows in this field. Although the widespread infection of hemophiliacs with the human immunodeficiency virus (HIV) contaminting clotting factor concentrates is still a threatening and formidable shadow, the gloomy picture brought about by the AIDS epidemic is partially lightened by spectacular improvements in therapy and diagnosis. Carrier detection and first-trimester prenatal diagnosis can now be performed accurately in most kindreds by analysis of DNA of the factor VIII or IX genes. An important step forward towards the elimination of the risk of blood-borne infections transmitted by plasma products was recently made through the application of virucidal methods to clotting factor concentrates. Since HIV appears more vulnerable to such methods than the hepatitis viruses, currently available concentrates can be considered substantially free from the risk of transmitting HIV infection. Even though transmission of hepatitis is much reduced but not totally abolished, virucidal methods are continuously being improved, so that it can be foreseen that concentrates will become safer and safer. Finally, factor VIII produced by recombinant DNA technology is undergoing the first clinical trials in hemophiliacs. Hopefully, it will free from the risk of transmitting infections and will be available in sufficiently large amounts to meet the need of hemophiliacs worldwide.

AB - Since 1982, when the World Federation of Hemophilia first published a document on the state of the art of hemophilia diagnosis and care, there have been lights and shadows in this field. Although the widespread infection of hemophiliacs with the human immunodeficiency virus (HIV) contaminting clotting factor concentrates is still a threatening and formidable shadow, the gloomy picture brought about by the AIDS epidemic is partially lightened by spectacular improvements in therapy and diagnosis. Carrier detection and first-trimester prenatal diagnosis can now be performed accurately in most kindreds by analysis of DNA of the factor VIII or IX genes. An important step forward towards the elimination of the risk of blood-borne infections transmitted by plasma products was recently made through the application of virucidal methods to clotting factor concentrates. Since HIV appears more vulnerable to such methods than the hepatitis viruses, currently available concentrates can be considered substantially free from the risk of transmitting HIV infection. Even though transmission of hepatitis is much reduced but not totally abolished, virucidal methods are continuously being improved, so that it can be foreseen that concentrates will become safer and safer. Finally, factor VIII produced by recombinant DNA technology is undergoing the first clinical trials in hemophiliacs. Hopefully, it will free from the risk of transmitting infections and will be available in sufficiently large amounts to meet the need of hemophiliacs worldwide.

UR - http://www.scopus.com/inward/record.url?scp=0024589588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024589588&partnerID=8YFLogxK

M3 - Article

C2 - 2658317

AN - SCOPUS:0024589588

VL - 56

SP - 141

EP - 144

JO - Vox Sanguinis

JF - Vox Sanguinis

SN - 0042-9007

IS - 3

ER -